Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy

OBJECTIVE:To determine whether rituximab 375 mg/m was efficacious in patients with immunoglobulin M (IgM) anti-myelin–associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy). METHODS:Fifty-four patients with IgM anti-MAG demyelinating neuropathy were enrolle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2013-06, Vol.80 (24), p.2217-2225
Hauptverfasser:	Léger, Jean-Marc, Viala, Karine, Nicolas, Guillaume, Créange, Alain, Vallat, Jean-Michel, Pouget, Jean, Clavelou, Pierre, Vial, Christophe, Steck, Andreas, Musset, Lucile, Marin, Benoit
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - therapeutic use Biological and medical sciences Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction Demyelinating Diseases - drug therapy Demyelinating Diseases - immunology Demyelinating Diseases - pathology Double-Blind Method Female Follow-Up Studies Humans Immunoglobulin M - biosynthesis Male Medical sciences Middle Aged Myelin-Associated Glycoprotein - immunology Nervous system (semeiology, syndromes) Neurology Polyneuropathies - drug therapy Polyneuropathies - immunology Polyneuropathies - pathology Rituximab Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!